Journal ArticleDOI
The 2001 Bethesda System: terminology for reporting results of cervical cytology.
Diane Solomon,Diane D. Davey,Robert J. Kurman,Marianne U. Prey,Stephen S. Raab,Mark E. Sherman,David C. Wilbur,Nancy A. Young +7 more
TLDR
The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.Abstract:
ObjectivesThe Bethesda 2001 Workshop was convened to evaluate and update the 1991
Bethesda System terminology for reporting the results of cervical cytology.
A primary objective was to develop a new approach to broaden participation
in the consensus process.ParticipantsForum groups composed of 6 to 10 individuals were responsible for developing
recommendations for discussion at the workshop. Each forum group included
at least 1 cytopathologist, cytotechnologist, clinician, and international
representative to ensure a broad range of views and interests. More than 400
cytopathologists, cytotechnologists, histopathologists, family practitioners,
gynecologists, public health physicians, epidemiologists, patient advocates,
and attorneys participated in the workshop, which was convened by the National
Cancer Institute and cosponsored by 44 professional societies. More than 20
countries were represented.EvidenceLiterature review, expert opinion, and input from an Internet bulletin
board were all considered in developing recommendations. The strength of evidence
of the scientific data was considered of paramount importance.Consensus ProcessBethesda 2001 was a year-long iterative review process. An Internet
bulletin board was used for discussion of issues and drafts of recommendations.
More than 1000 comments were posted to the bulletin board over the course
of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to
the public. Postworkshop recommendations were posted on the bulletin board
for a last round of critical review prior to finalizing the terminology.ConclusionsBethesda 2001 was developed with broad participation in the consensus
process. The 2001 Bethesda System terminology reflects important advances
in biological understanding of cervical neoplasia and cervical screening technology.read more
Citations
More filters
Journal ArticleDOI
Detection of Hypermethylated Genes in Women with and Without Cervical Neoplasia
Qinghua Feng,Akhila Balasubramanian,Stephen E. Hawes,Papa Toure,Papa Salif Sow,Ahmadou Dem,B. Dembele,Cathy W. Critchlow,Longfu Xi,Hiep Lu,Martin W. McIntosh,Alicia M. Young,Nancy B. Kiviat +12 more
TL;DR: Aberrant promoter methylation analysis on exfoliated cell samples is a potential diagnostic tool for cervical cancer screening that potentially may be used alone or in conjunction with cytology and/or human papillomavirus testing.
Journal ArticleDOI
Cervical Cancer Prevention - Cervical Screening: Science in Evolution
TL;DR: The traditional methods of screening for cervical cancer and innovative methods that might help overcome financial and cultural barriers to more widespread screening are described.
Journal ArticleDOI
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
Hormuzd A. Katki,Mark Schiffman,Philip E. Castle,Barbara Fetterman,Nancy Poitras,Thomas Lorey,Li C. Cheung,Tina Raine-Bennett,Julia C. Gage,Walter Kinney +9 more
TL;DR: Using the principle of “equal management of equal risks,” benchmarking to implicit risk thresholds based on Pap-alone can be used to achieve safe and consistent incorporation of cotesting.
Journal ArticleDOI
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
Elmar A. Joura,Susanne K. Kjaer,Cosette M. Wheeler,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,Xavier Bosch,Joakim Dillner,Robert J. Kurman,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Lisa Lupinacci,Katherine E.D. Giacoletti,Shuang Lu,Scott Vuocolo,Teresa M. Hesley,Richard M. Haupt,Eliav Barr +37 more
TL;DR: Results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers, in women vaccinated at day 1 and at 6-12 months intervals for up to 48 months is suggested.
Journal ArticleDOI
Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women
TL;DR: Six years after licensure of the quadrivalent HPV vaccine in Denmark, a reduced risk of cervical lesions is observed at the population level.
References
More filters
Journal ArticleDOI
Natural history of cervicovaginal papillomavirus infection in young women
TL;DR: An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners.
Journal ArticleDOI
Natural History of Cervicovaginal Papillomavirus Infection in Young Women Gyf Ho
TL;DR: The incidence of HPV infection in sexually active young college women is high and the short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively.
Journal ArticleDOI
Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis
TL;DR: Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis.
Journal ArticleDOI
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
TL;DR: Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASC-US) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (asc-H).
Journal ArticleDOI
Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial
TL;DR: HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS and has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.